Top ▲


Disease ID:1227
Associated with:0 target
1 immuno-relevant ligand
A myopathy characterized by muscle inflammation.
Database Links
Disease Ontology: DOID:633
OMIM: 160750


No target related data available for Myositis


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: In clinical trial for this indication- see NCT02347891.
Clinical Use: Approved as an adjunctive treatment for systematic lupus erythematosus (SLE) [1]. The original formulation of belimumab was administered intravenously. In July 2017, a new self-injectable subcutaneous formulation of belimumab for the treatment of adult patients with active, autoantibody‑positive SLE was FDA approved, which allows patients to self-administer their medicine at home rather than going to medical facilities to receive their i.v. infusions.
Additional indications being evaluated with belimumab include vasculitis (Phase 3), and myaesthenia gravis and transplant rejection (both Phase 2). | View clinical data


Show »

1. Lutalo PM, D'Cruz DP. (2014) Update on belimumab for the management of systemic lupus erythematosus. Expert Opin Biol Ther, 14 (11): 1701-8. [PMID:25303323]